Cambridge, Mass. and Lausanne, Switzerland, Oct. 12, 2023 – Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today it will present data from the completed Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial that evaluated KAN-101 as a treatment for celiac disease during an oral presentation at the United European Gastroenterology (UEG) Week 2023. The encore presentation will feature the favorable pharmacodynamic and pharmacokinetic data from the Phase 1 trial, which showed KAN-101 was safe and tolerated in people with celiac disease and induced functional tolerance of gliadin-specific T-cell responses after gluten challenge.
“We look forward to discussing the data from our initial Phase 1 study with KAN-101 for celiac disease with the scientific and medical community, as this investigational immune tolerance therapy demonstrated impact on key biomarkers in celiac disease and supported the recent Phase 2 initiation of our global program,” said Deborah Geraghty, Ph.D., chief executive officer of Anokion.
The oral presentation titled, “Pharmacodynamic Demonstration of Immunological Tolerance Induced by KAN-101, a Novel Liver-Targeted Therapy for Coeliac Disease, Persists Following Drug Clearance,” will take place on Monday, October 16 at 4:00 p.m. CEST during UEG Week in Copenhagen.
Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease. For more information, please visit anokion.com.
THRUST Strategic Communications